Brief: Scynexis And GSK Resolve Their Disagreement Related To The Restart Of The Phase 3 MARIO Study
15/10/2025 13:02
Oct 15 (Reuters) - GSK plc GSK.L: SCYNEXIS AND GSK RESOLVE THEIR DISAGREEMENT RELATED TO THE RESTART OF THE PHASE 3 MARIO STUDY SCYNEXIS INC - TO RECEIVE $22 MILLION PAYMENT RELATED TO PHASE 3 MARIO STUDY SCYNEXIS INC - TO TERMINATE PHASE 3 MARIO STUDY SCYNEXIS INC - GSK PAYMENT EXTENDS SCYNEXIS CASH RUNWAY TO OVER TWO YEARS SCYNEXIS INC - TO RECEIVE ADDITIONAL $2.3 MILLION FOR WIND-DOWN ACTIVITIES Source text: ID:nGNX9LzfT5 Further company coverage: GSK.L
Recent news on Scynexis
See all newsBrief: Scynexis Announces Phase 1 Study Results For Scy-770, A Novel, Highly Selective, Oral Direct Ampk Activator For The Treatment Of Autosomal Dominant Polycystic Kidney Disease
Brief: Scynexis Announces Appointment Of Sanjay Subramanian As Chief Financial Officer
Scynexis Inc Reports Results For The Quarter Ended June 30: Earnings Summary
Scynexis Q2 swings to profit on warrant adjustment; advances drug studies
Scynexis Inc Expected To Post A Loss Of 51 Cents A Share: Earnings Preview